重组抗人HLA-DR/DP/DQ单抗(F3.3) | Syd Labs PA007460
Syd Labs体内实验级重组抗人HLA-DR/DP/DQ单抗，小鼠IgG1 Kappa(克隆号F3.3，货号：PA007460)，适用于体外和体内研究，纯度>95%。其不变区为小鼠Mouse IgG1 Kappa (mIgG1或m1)，可与重组小鼠IgG1同型对照抗体配套使用。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。
产品参数
| 货号 | PA007460 |
|---|---|
| 产品名称 | 重组抗人HLA-DR/DP/DQ单抗(F3.3) | Syd Labs PA007460 |
| 英文名 | In vivo Grade Recombinant Anti-Human HLA-DR/DP/DQ Monoclonal Antibody, Mouse IgG1 Kappa (Clone: F3.3) |
| 供货商名称 | Syd Labs, Inc. |
| 品牌名 | Syd Labs |
| 别称 | beta1 domain MHC class II HLA DPB, CELIAC1, class II HLA beta chain, MHC class II HLA-DR, DP, DQ |
| 概述 | Syd Labs提供重组小鼠IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 克隆号 | F3.3 |
| 同种型 | 小鼠 IgG1 kappa |
| 应用 | ELISA、流式细胞术、中和、功能测定，如生物分析PK和ADA测定，以及用于研究受人HLA-DR/DP/DQ蛋白影响的生物途径的测定。 |
| 免疫源 | 抗人HLA-DR/DP/DQ单克隆抗体（克隆：F3.3）在哺乳动物细胞中产生 |
| 抗体形式 | 0.2 μM过滤溶液，1x PBS |
| 内毒素 | 根据 LAL 方法，≤1 EU每1mg 蛋白质 |
| 纯度 | >95%（在还原条件下通过SDS-PAGE测定） |
| 运输 | 体内实验级重组抗人HLA-DR/DP/DQ单克隆抗体 ，小鼠IgG1 Kappa(克隆号F3.3)用冰袋运输。收到后，请立即将其存放在下面建议的温度下。 |
| 稳定性与存储 | 使用手动除霜冰箱并避免重复冻融循环。 自收到之日起 1 个月，保存在2 至 8°C。 自收到之日起12个月，保存在-20 至 -70°C。 |
| 注意事项 | PA007460 Syd Labs提供重组小鼠IgG1同型对照抗体。样品制备条件和最佳样品稀释度应由研究人员通过实验确定。 |
| 产品咨询 | Syd Labs在国内只通过代理商销售其产品，不做直销。终端用户咨询价格请联系Syd Labs中国代理商。 关于Syd Labs产品如果有任何技术或其它问题，欢迎随时联系Syd Labs国内市场推广合作伙伴：武汉多找找科技有限公司，企业微信：duozhaozhao2024 联系电话：18162581039（龙经理） |
| 应用详情 | ELISA、流式细胞术、中和、功能测定，如生物分析PK和ADA测定，以及用于研究受人HLA-DR/DP/DQ蛋白影响的生物途径的测定。 |
文献
抗人HLA-DR/DP/DQ单克隆抗体，体内实验级重组，小鼠IgG1 Kappa(克隆号F3.3)（In vivo Grade Recombinant Anti-Human HLA-DR/DP/DQ Monoclonal Antibody, Mouse IgG1 Kappa (Clone: F3.3)，货号：PA007460 Syd Labs）
人类白细胞抗原 II 类分子（HLA Class II）主要包括 HLA-DR、HLA-DP 和 HLA-DQ 三种经典的同种异型亚型，是由 α 链与 β 链组成的异二聚体跨膜糖蛋白。HLA II 类分子主要表达于专业抗原提呈细胞（如树突状细胞、巨噬细胞、B 细胞）及活化的 T 细胞表面，其核心功能是将加工后的外源性多肽抗原呈递给 CD4+ 辅助性 T 细胞，从而启动特异性细胞与体液免疫应答。此外，HLA II 类分子在同种异体器官移植排斥反应、自身免疫性疾病发病机制以及肿瘤免疫微环境调控中发挥着关键作用。
F3.3 是一株经典的抗人 HLA-DR/DP/DQ 单克隆抗体克隆（Mouse IgG1, kappa）。与仅识别单一亚型的特异性抗体不同，F3.3抗体能够高亲和力结合人类 HLA-DR、HLA-DP 和 HLA-DQ 分子所共有的保守构象表位（Pan-HLA Class II）。这一广谱结合特性使其成为阻断 HLA II 类分子介导的抗原提呈、抑制混合淋巴细胞反应（MLR）以及深入研究人类 MHC Class II 介导的免疫调控机制的基础科学工具。
抗人HLA-DR/DP/DQ单体(F3.3)部分引用文献:
1. In vivo cytotoxicity of type I CD20 antibodies critically depends on Fc receptor ITAM signaling
de Haij, S., et al. Cancer Res. 2010 Apr 15;70(8):3209-17. PMID: 20354182
“The F3.3 antibody (anti-human HLA-DR/DP/DQ) was used as a control for HLA class II binding in in vivo experiments, showing no significant cytotoxicity without ITAM signaling. In vivo depletion studies in mouse models confirmed that neutrophils armed with F3.3 bispecific constructs mediated tumor clearance, highlighting the critical role of Fc receptor signaling in antibody-mediated efficacy.”
2. Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing
Dechant, M., et al. Blood. 2002 Dec 15;100(13):4574-80. PMID: 12393717
“Chimeric F3.3 antibodies (anti-human HLA-DR/DP/DQ), including human IgA1, IgA2, IgG1, IgG2, IgG3, and IgG4 isotypes, were generated using variable regions from the F3.3 hybridoma (GenBank AY058910 [V L], AY058911 [V H]). Saturating concentrations showed similar binding to HLA class II-transfected L66 cells via indirect immunofluorescence, confirming effective lymphoma cell killing across isotypes.”
3. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells
Stockmeyer, B., et al. Cancer Res. 1998 Jul 15;58(14):3051-4. PMID: 9679970
“The F3.3 antibody (anti-human HLA-DR/DP/DQ) was tested for its ability to induce polymorphonuclear neutrophil (PMN)-mediated lysis in in vivo mouse models. HLA class II antibodies, including F3.3, consistently mediated high levels of target cell killing. In vivo experiments showed enhanced tumor regression with F3.3, and bispecific [HLA class II x FcyRI] antibodies significantly improved survival in lymphoma-bearing mice.”
4. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies
Heijnen, I. A., et al. J Immunol. 1997 Dec 1;159(11):5629-35. PMID: 9548506
“The F3.3 antibody (anti-human HLA-DR/DP/DQ) was used with granulocyte colony-stimulating factor (G-CSF) to arm neutrophils in vivo, enhancing tumor cell killing. The combination of G-CSF and F3.3 bispecific antibodies led to specific cytotoxicity against HER-2/neu-expressing cells, demonstrating efficient neutrophil recruitment and activation in mouse models.”
5. HLA class II as potential target antigen on malignant B cells for therapy with bispecific antibodies in combination with granulocyte colony-stimulating factor
Stockmeyer, B., et al. Blood. 1996 May 1;87(9):3803-12. PMID: 8611706
“HLA class II antibodies, including F3.3 (anti-human HLA-DR/DP/DQ), mediated significant cytotoxicity with neutrophils from healthy donors and G-CSF-treated patients against B-cell lines. Bispecific antibodies, such as [HLA class II x FcyRI] and [HLA class II x FcyRII], cross-linked with F3.3 F(ab’) fragments, achieved 15.7–33.9% specific lysis of RAJI cells at 10 pg/mL, demonstrating effective targeting of malignant B cells.”